Table 2.
Testosterone treatment-related parameters in patients who failed to show a maintained response (Group I) and those with a maintained response (Group II) after TRT cessation.
| Group I | Group II | p-Value | |
|---|---|---|---|
| Baseline TT (ng/dL) | 323.0 ± 15.4 | 325.2 ± 19.8 | 0.221 |
| Highest TT (ng/dL) | 546.1 ± 230.3 | 713.7 ± 139.2 | 0.000 |
| ∆ (Highest–Baseline)TT (ng/dL) | 223.0 ± 231.1 | 388.5 ± 244.0 | 0.000 |
| TRT duration (months) | 5.2 ± 4.4 | 10.7 ± 9.5 | 0.000 |
| Type of TRT, N (%) | 0.347 | ||
| Oral TU | 15/92 (16.3) | 9/59 (15.3) | |
| T-gel | 44/92 (47.8) | 31/59 (52.4) | |
| Injectable TE | 13/92 (14.1) | 5/59 (8.5) | |
| Injectable TU | 10/92 (10.9) | 9/59 (15.3) | |
| Mixed | 10/92 (10.9) | 5/59 (8.5) | |
| IIEF total | 35.01 ± 10.04 * | 34.92 ± 10.17 * | 0.955 |
| Erectile function | 14.27 ± 5.34 * | 14.14 ± 5.26 * | 0.878 |
| Orgasmic function | 5.08 ± 2.84 * | 5.10 ± 2.80 * | 0.957 |
| Sexual desire | 5.47 ± 1.84 * | 5.30 ± 1.81 * | 0.576 |
| Intercourse satisfaction | 5.79 ± 2.08 * | 5.71 ± 2.16 * | 0.817 |
| Overall satisfaction | 4.76 ± 1.73 * | 4.80 ± 1.76 * | 0.902 |
| AMS total | 32.332 ± 6.02 * | 32.49 ± 6.28 * | 0.871 |
| Psycho | 7.49 ± 2.11 * | 7.56 ± 2.08 * | 0.841 |
| Somato | 11.42 ± 2.90 * | 11.42 ± 2.75 * | 0.885 |
| Sexual | 13.38 ± 3.80 * | 13.47 ± 4.02 * | 0.885 |
| PSA (ug/dL) | 1.23 ± 0.91 ¥ | 1.31 ± 0.93 ¥ | 0.723 |
| Hb (g/dL) | 15.21 ± 1.21 * | 15.31 ± 1.05 * | 0.755 |
| Hct (%) | 45.21 ± 3.81 * | 45.70 ± 3.85 * | 0.760 |
p-value, compared between two groups using the independent t-test; TRT, testosterone replacement therapy; TT, serum total testosterone level; ∆, increase in TT level; TU, testosterone undecanoate; T-gel, 2% testosterone gel; TE, testosterone enanthate; Mixed, in the case of using more than one form of TRT; PSA, prostate-specific antigen; Hb, hemoglobin; Hct, hematocrit; *, p < 0.01, compared to baseline in each group using the paired t-test; ¥, p < 0.05, compared to baseline in each group using the paired t-test.